Market Report Source

Overview

The prevalence of asthma in 2005 across the US, Japan, France, Germany, Spain, Italy and the UK was estimated at 53.2m people, corresponding to a prevalence rate of 7.7%. The highest prevalence rate for asthma in any country in 2005 was 12.0% in the UK. It is forecast that by 2011, the total prevalence of asthma across the seven major markets will be 58.8m sufferers or 8.0% of the population. COPD is only significantly prevalent in adults, a contrary situation to that of asthma, in which pediatric patients are estimated to represent some 35% of the total asthmatic patient population across the 7 major markets. 56.4m individuals are estimated to suffer from COPD across the seven major markets, although extremely low rates of diagnosis are thought to have resulted in a treated population of less than 10m individuals. Increasingly, COPD is becoming a major disease burden across the seven major markets, with a forecast patient population of 60.8m individuals by 2011, indicating high levels of future patient potential. Currently the treatment of asthma/COPD favors the use of beta-2 agonists and inhaled corticosteroids, with leukotriene antagonists and anticholinergics being positioned as additional therapies in either pediatric or last-line patients. With an estimated patient potential of 1.5bn in 2005, allergic rhinitis (AR) is associated with the largest disease burden of any major chronic respiratory disease by virtue of its high prevalence and its impacts on quality of life and productivity. It is believed that AR and asthma frequently co-exist and AR is a significant risk factor for asthma. Across the seven major markets, the prevalence of AR is forecast to increase to 1.8bn individuals in 2011, driven by the effect of raised levels of allergenic exposure, in both indoor and outdoor environments.

Table of Contents

Table of Contents

The Asthma, COPD and Allergic Rhinitis Market

Outlook to

Executive Summary

Patient potential

Global market analysis

Analysis of future potential respiratory blockbusters

Leading players in the respiratory market

Chapter 1 Patient potential

Summary

Introduction

Asthma

Overview

Diagnosis, treatment and management

Epidemiology

Chronic Obstructive Pulmonary Disease (COPD)

Overview

Diagnosis, treatment and management

Epidemiology

Allergic rhinitis

Overview

Diagnosis, treatment and management

Epidemiology

Chapter 2 Global market analysis

Summary

Introduction

Respiratory market analysis by drug class

iv

Leading respiratory brand dynamics

Asthma/COPD market analysis

Introduction

Asthma/COPD drug classes

Leading brands in the asthma/COPD market

SABA/LABA therapies

Leading brands in the global SABA/LABA market

Overview/market dynamics

Key brands analysis

Inhaled corticosteroids

Leading brands in the global ICS market

Overview/market dynamics

Key brands analysis

Combination LABA/ICS products

Leading brands in the global combination LABA/ICS market

Overview/market dynamics

Key brands analysis

Leukotriene antagonists

Leading brands in the global leukotriene antagonist market

Overview/market dynamics

Key brands analysis

Anticholinergics/anticholinergics combination products

Leading brands in the global anticholinergic market

Overview/market dynamics

Key brands analysis

Asthma/COPD class forecasts to 2011

Allergic rhinitis market analysis

Introduction

Allergic rhinitis drug classes

Leading brands in the allergic rhinitis market

Anti-histamines

Leading brands in the global antihistamines market

Overview/market dynamics

Key brands analysis

Nasal corticosteroids

Leading brands in the global nasal corticosteroid market

Overview/market dynamics

Key brands analysis

Allergic rhinitis class forecasts to 2011

Chapter 3 Analysis of future potential respiratory blockbusters

Summary

Introduction

Major approaches to R&D

v

Drug profiles

Phase II pipeline drugs

Super Advair (fluticasone/salmeterol)

EPI-12323

Phase III pipeline drugs

QAB149 (indacaterol)

Allermist/Avamys (fluticasone furoate)

Flutiform (formoterol/fluticasone)

Drugs in registration

arformoterol

Alvesco (ciclesonide)

Daxas (roflumilast)

Ariflo (cilomilast)

Recently marketed drugs

Xolair (omalizumab)

Asmanex (mometasone)

Forecast sales potential

Chapter 4 Leading players in the respiratory market

Summary

Introduction

Global market shares

GlaxoSmithKline

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Merck & Co.

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Boehringer Ingelheim

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

AstraZeneca

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Schering-Plough

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Sanofi-Aventis

vi

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Pfizer

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Novartis

Marketed products

R&D compounds

Respiratory portfolio sales forecasts to 2011

Chapter 5 Appendix

IMS sales data

Glossary

Index

vii

List of Figures

Figure 1.1: Estimated proportion of patients presenting with asthma that are correctly diagnosed

by physician visit

Figure 1.2: Typical treatment patterns in the treatment of asthma

Figure 1.3: Typical treatment patterns in COPD

Figure 1.4: Classification of allergic rhinitis

Figure 1.5: Treatment of allergic rhinitis across different stages of disease progression

Figure 2.6: Competitive dynamics of drug classes within the global respiratory market, 2005

Figure 2.7: Competitive dynamics of leading brands in the global respiratory market, 2005

Figure 2.8: Competitive dynamics of drug classes within the global asthma/COPD market, 2005

Figure 2.9: Competitive dynamics of leading brands in the global asthma/COPD market, 2005

Figure 2.10: Competitive dynamics of drug classes within the allergic rhinitis market, 2005

Figure 2.11: Competitive dynamics of leading brands in the AR market, 2005

Figure 3.12: Leading recently launched respiratory products and compounds in R&D, 2006

Figure 3.13: Prevailing R&D approaches, 2006

Figure 4.14: Key players in the global respiratory market, 2001 & 2005

List of Tables

Table 1.1: Estimated prevalence of asthma in across seven major markets, 2005

Table 1.2: Forecast epidemiology of asthma across the seven major markets, 2005-11

Table 1.3: Estimated prevalence of COPD in across seven major markets, 2005

Table 1.4: Forecast epidemiology of COPD across the seven major markets, 2005-11

Table 1.5: Estimated prevalence of allergic rhinitis in across seven major markets, 2005

Table 1.6: Forecast epidemiology of allergy rhinitis across the seven major markets, 2005-11

Table 2.7: Breakdown of the global respiratory market by drug class, 2001–05

Table 2.8: Leading products in the global respiratory market, 2004–05

Table 2.9: Breakdown of the global asthma/COPD market by drug class, 2001–05

Table 2.10: Leading asthma/COPD products in the global respiratory market, 2004–05

Table 2.11: Leading SABA/LABA brands in the global respiratory market, 2004–05

Table 2.12: Leading ICS brands in the global respiratory market, 2004–05

Table 2.13: Leading combination LABA/ICS brands in the global respiratory market, 2004–05

Table 2.14: Leading leukotriene antagonist brands in the global respiratory market, 2004–05

Table 2.15: Leading anticholinergic brands in the global respiratory market, 2004–05

Table 2.16: Sales forecasts for classes in the asthma/COPD market, 2005–11

Table 2.17: Breakdown of the global allergy rhinitis market by drug class, 2001–05

Table 2.18: Leading allergic rhinitis products in the global respiratory market, 2004–05

Table 2.19: Leading antihistamine brands in the global respiratory market, 2004–05

Table 2.20: Leading nasal corticosteroid brands in the global respiratory market, 2004–05

Table 2.21: Sales forecasts for allergic rhinitis classes, 2005–11

Table 3.22: Sales forecasts for promising pipeline and recently launched compounds in R&D,

2005–11

viii

Table 4.23: Key players in the global respiratory market, 2001-05

Table 4.24: GSK’s marketed respiratory portfolio, 2004-05

Table 4.25: GSK’s respiratory R&D pipeline, 2006

Table 4.26: Forecast sales for GSK’s respiratory portfolio, 2005–11

Table 4.27: Merck & Co’s marketed respiratory portfolio, 2004-05

Table 4.28: Merck & Co.’s respiratory R&D pipeline, 2006

Table 4.29: Forecast sales for Merck & Co.’s respiratory portfolio, 2005–11

Table 4.30: Boehringer Ingelheim’s marketed respiratory portfolio, 2004-05

Table 4.31: Forecast sales for BI’s respiratory portfolio, 2005–11

Table 4.32: AstraZeneca’s marketed respiratory portfolio, 2004-05

Table 4.33: AstraZeneca’s respiratory R&D pipeline, 2006

Table 4.34: Forecast sales for AstraZeneca’s respiratory portfolio, 2005–11

Table 4.35: Schering-Plough’s marketed respiratory portfolio, 2004-05

Table 4.36: Schering-Plough’s respiratory R&D pipeline, 2006

Table 4.37: Forecast sales for Schering-Plough’s respiratory portfolio, 2005–11

Table 4.38: Sanofi-Aventis’ marketed respiratory portfolio, 2004-05

Table 4.39: Sanofi-Aventis’ respiratory R&D pipeline, 2006

Table 4.40: Forecast sales for Sanofi-Aventis’ respiratory portfolio, 2005–11

Table 4.41: Pfizer’s marketed respiratory portfolio, 2004-05

Table 4.42: Pfizer’s respiratory R&D pipeline, 2006

Table 4.43: Forecast sales for Pfizer’s respiratory portfolio, 2005–11

Table 4.44: Novartis’ marketed respiratory portfolio, 2004-05

Table 4.45: Novartis’ respiratory R&D pipeline, 2006

Table 4.46: Forecast sales for Novartis’ respiratory portfolio, 2005–11 156